Attovia Therapeutics, Inc. (ATTO) Stock Analysis
A live, multi-source view of Attovia Therapeutics, Inc. (ATTO): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Attovia Therapeutics, Inc.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Sector: Healthcare · Industry: Biotechnology · United States · 44 employees · attovia.com
Key statistics · as of 2026-09-10
As of 2026-09-10, Attovia Therapeutics, Inc. (ATTO) had a market capitalization of $1.04B (forward -9.6); the shares traded in a 52-week range of $16.15 – $28.00 (4.4% over the year).
- Market cap
- $1.04B
- Enterprise value
- $1.19B
- Forward P/E
- -9.6
- EPS (trailing)
- $-1.58
- EPS (forward)
- $-2.38
- Payout ratio
- 0.0%
- 52-week range
- $16.15 – $28.00
- 52-week change
- 4.4%
- Average volume
- 444,968
- Shares outstanding
- 45.7M
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of ATTO; corporate insiders filed 9 buys and 46 sells (6 distinct filers, latest disclosure 2026-08-13). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Colin Walsh (2B/23S), Goldman Sachs Group Inc (2B/23S), Redmile Group, Llc (2B/0S), Venbio Global Strategic Fund Iv, L.p. (1B/0S), Sanofi (1B/0S), Frazier Life Sciences Xi, L.p. (1B/0S). Who is trading what
RapidTradeView pick record
ATTO has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Attovia Therapeutics, Inc. (ATTO) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell ATTO.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.